Morgan P. H. Thomas

Morgan P. H. Thomas

Auto-generated profile, based on publicly available information

Morgan P. H. Thomas

Leeds Institute of Medical Research at St James’s, University of Leeds , Leeds

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in iScience
Verified
Journal Article
Open access
BMBeatrice Malacrida
Beatrice Malacrida
SNSam Nichols
Sam Nichols
EMEleni Maniati
Eleni Maniati
RJRoanne Jones
Roanne Jones
RDRobin Delanie-Smith
Robin Delanie-Smith
OPOliver M.T. Pearce
Oliver M.T. Pearce
Guided by a multi-level “deconstruction” of omental metastases, we developed a tetra (four cell)-culture model of primary human mesothelial cells, fibroblasts, adipocytes, and high-grade serous ovarian cancer (HGSOC) cell lines. This multi-cellular model replicated key elements of human metastases and allowed malignant cell invasion into the artificial omental structure. Prompted by findings in patient biopsies, we used the model to investigate the role of platelets in malignant cell invasion and extracellular matrix, ECM, production. RNA (sequencing and quantitative polymerase-chain reaction), protein (proteomics and immunohistochemistry) and image analysis revealed that platelets stimulated malignant cell invasion and production of ECM molecules associated with poor prognosis. Moreover, we found that platelet activation of mesothelial cells was critical in stimulating malignant cell invasion. Whilst platelets likely activate both malignant cells and mesothelial cells, the tetra-culture model allowed us to dissect the role of both cell types and model the early stages of HGSOC metastases.

1 February 2025 in Neuro-Oncology
Verified
Journal Article
Open access
MTMorgan P H Thomas
Morgan P H Thomas
SAShoaib Ajaib
Shoaib Ajaib
GTGeorgette Tanner
Georgette Tanner
ABAndrew J Bulpitt
Andrew J Bulpitt
LSLucy Stead
Lucy Stead
Background: Glioblastoma (GBM) presents a significant clinical challenge due to its aggressive nature and extensive heterogeneity. Tumor purity, the proportion of malignant cells within a tumor, is an important covariate for understanding the disease, having direct clinical relevance or obscuring signal of the malignant portion in molecular analyses of bulk samples. However, current methods for estimating tumor purity are nonspecific and technically demanding. Therefore, we aimed to build a reliable and accessible purity estimator for GBM. Methods: We developed GBMPurity, a deep learning model specifically designed to estimate the purity of IDH-wild type primary GBM from bulk RNA-sequencing (RNA-seq) data. The model was trained using simulated pseudobulk tumors of known purity from labeled single-cell data acquired from the GBmap resource. The performance of GBMPurity was evaluated and compared to several existing tools using independent datasets. Results: GBMPurity outperformed existing tools, achieving a mean absolute error of 0.15 and a concordance correlation coefficient of 0.88 on validation datasets. We demonstrate the utility of GBMPurity through inference on bulk RNA-seq samples and observe reduced purity of the proneural molecular subtype relative to the classical, attributed to the increased presence of healthy brain cells. Conclusions: GBMPurity provides a reliable and accessible tool for estimating tumor purity from bulk RNA-seq data, enhancing the interpretation of bulk RNA-seq data and offering valuable insights into GBM biology. To facilitate the use of this model by the wider research community, GBMPurity is available as a web-based tool at: https://gbmdeconvoluter.leeds.ac.uk/.

16 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMorgan P. H. Thomas
Morgan P. H. Thomas
SAShoaib Ajaib
Shoaib Ajaib
GTGeorgette Tanner
Georgette Tanner
ABAndrew J. Bulpitt
Andrew J. Bulpitt
LSLucy Stead
Lucy Stead
Background Glioblastoma (GBM) presents a significant clinical challenge due to its aggressive nature and extensive heterogeneity. Tumour purity, the proportion of malignant cells within a tumour, is an important covariate for understanding the disease, having direct clinical relevance or obscuring signal of the malignant portion in molecular analyses of bulk samples. However, current methods for estimating tumour purity are non-specific, unreliable or technically demanding. Therefore, we aimed to build a reliable and accessible purity estimator for GBM. Methods We developed GBMPurity, a deep learning model specifically designed to estimate the purity of IDH-wildtype primary GBM from bulk RNA-seq data. The model was trained using simulated pseudobulk tumours of known purity from labelled single-cell data acquired from the GBmap resource. The performance of GBMPurity was evaluated and compared to several existing tools using independent datasets. Results GBMPurity outperformed existing tools, achieving a mean absolute error of 0.15 and a concordance correlation coefficient of 0.88 on validation datasets. We demonstrate the utility of GBMPurity through inference on bulk RNA-seq samples and reveal reduced purity of the Proneural molecular subtype attributed to increased presence of healthy brain cells. Conclusions GBMPurity provides a reliable and accessible tool for estimating tumour purity from bulk RNA-seq data, enhancing the interpretation of bulk RNA-seq data and offering valuable insights into GBM biology. To facilitate the use of this tool by the wider research community, GBMPurity is available as a web-based tool at: https://gbmdeconvoluter.leeds.ac.uk/. Key Points GBMPurity is a glioblastoma-specific purity estimation tool. The model accurately estimates the purity of bulk RNA-seq data, outperforming existing tools. The model is available online at: https://gbmdeconvoluter.leeds.ac.uk/. Importance of the Study Glioblastoma (GBM) is a deadly brain tumour with a dismal prognosis. Research on this disease has lagged compared to other cancers, underscoring the need to streamline investigations. The cellular composition of the GBM tumour microenvironment significantly influences therapy resistance, prognosis, and the molecular state of neoplastic cells. Consequently, tumour purity (the proportion of malignant cells within a tumour) is a critical variable for understanding and contextualizing molecular and clinical analyses. We present GBMPurity (https://gbmdeconvoluter.leeds.ac.uk/), an accessible, GBM-specific tool that accurately predicts sample purity from bulk RNA-seq data. This tool can be used by the wider research community to support the interpretation of bulk omics data and accelerate the identification of more effective therapeutic strategies for treating GBM.